What’s Really Going on with CRSP — And What You Need to KnowCRISPR Therapeutics AGBATS:CRSPseedIt’s Thursday morning. The stock has been dropping. You’re asking yourself: What the hell is going on? You’re seeing red in your portfolio, the option chain bleeding. Retail’s getting nervous. But here’s the thing you need to understand — and I want you to sit with this: The drop is the setup. Not the end. This is exactly how squeezes begin CRSP is down today — not because of bad news, but because the market makers are doing their job. Implied volatility is elevated ahead of earnings on Monday. Shorts are trying to apply pressure to shake loose retail hands. Option dealers are reducing exposure by selling stock — delta neutral hedging. It’s Thursday before earnings. This is when they suppress the price on purpose to cheapen contracts, reset expectations, and trap anyone not looking deep enough. And that’s where the opportunity lies. The mechanics you’re not being told Let’s break this down in raw numbers. CRSP short interest is 29.15 million shares. That’s about 38 percent of the float — nearly one in every two tradable shares is bet against this company. Cost to borrow is over 25 percent at peak, averaging 17.2 percent. Days to cover is 5.3 — meaning if every short had to cover at once, it would take over a full trading week of volume. Dark pool activity is now over 56 percent of daily volume. This isn’t retail playing games. This is big money loading the spring in silence. And the trap door is earnings. Why CRISPR Therapeutics is so misunderstood This isn’t a meme stock. It’s not a pipe dream. Co-founded by a Nobel Prize winner. First ever FDA-approved CRISPR gene therapy, exa-cel. Strategic partnerships with Vertex, Bayer, ViaCyte. Over 2.1 billion dollars in cash on hand. Pipelines in sickle cell, beta-thalassemia, solid tumors, diabetes, and early Alzheimer’s. This is the Tesla of gene editing, but the market still treats it like it’s in the garage. Why? Because legacy investors don’t understand how fast biotech is changing. Because analysts can’t model curing disease. Because the old guard is still trying to value a revolution using 1990s Excel sheets. Why the price is falling right now Let’s be honest. Shorts want you to sell. Dealers need to de-risk into earnings. IV crush is a real threat post-call. But here’s what they don’t expect. That retail is watching. Calculating. Waiting. This dip isn’t about failure — it’s about strategy. They want cheaper entries. They want to make the breakout more violent. They want to buy your shares at a discount before what could be one of the most important earnings calls in the company's history — this Monday, August 5th. The setup is unlike anything else on the market If the stock closes Friday anywhere near 64 to 66 dollars, and Monday earnings beat or hint at expanded trials, we get: Gamma exposure flipping from neutral to positive Dealers forced to hedge upward Shorts squeezed from multiple levels Price targeting 75 to 90 to 110 in a matter of weeks And every dollar higher costs shorts tens of millions in floating losses. They’re already down over 500 million since mid-June. A move above 75 brings many of those positions to 50 percent losses — the exact pain point where margin calls trigger. And when that starts? There’s no graceful exit. Final thoughts The world is sleeping on CRSP. But you’re not. You’re watching. You see the setup. You understand the math. You feel the potential. This is not financial advice. This is a call to wake up — to learn, to dig, to question what they want you to believe. Because just like with Tesla at 30 dollars… Apple in the garage… Amazon when it only sold books… The next generation of wealth won’t come from playing it safe. It comes from understanding the moment before it arrives. And this is one of those moments. Seed